Impact of coinfection with HIV-1 and GB virus C in patients receiving a ritonavir-boosted HAART regimen: a substudy to the MaxCmin1 trial.
Tillmann
Hans L
HL
Kaiser
Thorsten
T
Fox
Zoe
Z
Staszewski
Schlomo
S
Antunes
Francesco
F
Monforte
Antonella d'Arminio
Ad
Vernazza
Pietro
P
Hill
Andrew
A
Dragsted
Ulrik B
UB
Lundgren
Jens D
JD
D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D001118:Argentina; D002986:Clinical Trials as Topic; D005060:Europe; D018178:Flaviviridae Infections / Q000150:complications* / Q000175:diagnosis; D029407:GB virus C / Q000276:immunology; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D015497:HIV-1; D006525:Hepatitis, Viral, Human / Q000150:complications* / Q000175:diagnosis; D006801:Humans; D019438:Ritonavir / Q000627:therapeutic use*; D012698:Serologic Tests; D016896:Treatment Outcome; D014481:United States
D044966:Anti-Retroviral Agents; D017320:HIV Protease Inhibitors; D019438:Ritonavir